Hormone Molecular Biology and Clinical Investigation
Editor-in-Chief: Pasqualini, Jorge R.
Editorial Board Member: Fujimoto, Jiro / Groner, Bernd / Hubalek, Michael / Morfin, Robert / Saad, Farid / Schally, Andrew V. / Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Campagnoli, Carlo / Carruba, Giuseppe / Chen, Shiuan / Chetrite, Gerard / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Danza, Giovanna / Darbre, Philippa D. / Daxenbichler, Günter / Kloet, Ronald / Nicola, Alejandro F. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Flores-Morales, Amilcar / Garcia-Segura, Luis M. / Gee, J.M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Hilakivi-Clarke, Leena / Hampl, Richard / Iwase, Hirotaka / Jordan, V.Craig / Klocker, Helmut / Kurebayashi, Jyunichi / Labrie, Fernand / Luu-The, Van / Mendelson, Carole R. / Mück, Alfred O. / Nicholson, Robert / Norman, Anthony W. / O'Malley, Bert W. / Rafestin-Oblin, Marie-Edith / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Sanchez, Edwin R. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Verhoeven, Guido / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Ylikomi, Timo / Yu, Qi
12 Issues per year
Volume 20 (2014)
Volume 19 (2014)
Volume 18 (2014)
Volume 17 (2014)
Volume 16 (2013)
Volume 15 (2013)
Volume 14 (2013)
Volume 13 (2013)
Volume 12 (2012)
Volume 11 (2012)
Volume 10 (2012)
Volume 9 (2012)
Volume 8 (2011)
Volume 7 (2011)
Volume 6 (2011)
Volume 5 (2011)
Volume 3 (2010)
Volume 4 (2010)
Volume 2 (2010)
Most Downloaded Articles
- Enhanced Na+, K+-ATPase activity and endothelial modulation decrease phenylephrine-induced contraction in aorta from ouabain-treated normotensive and hypertensive rats by Davel, Ana Paula/ Couto, Gisele Kruger/ Wenceslau, Camilla Ferreira/ Peres, Emilia Cristina/ Xavier, Fabiano Elias and Rossoni, Luciana Venturini
- The role of leptin/adiponectin ratio in metabolic syndrome and diabetes by López-Jaramillo, Patricio/ Gómez-Arbeláez, Diego/ López-López, Jose/ López-López, Cristina/ Martínez-Ortega, Javier/ Gómez-Rodríguez, Andrea and Triana-Cubillos, Stefany
Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome
1Bayer Schering Pharma, Scientific Affairs Men’s Healthcare, Berlin, Germany
2Gulf Medical University School of Medicine, Ajman, United Arab Emirates
3Private Urology Praxis, Bremerhaven, Germany
4Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands
5Endocrinology, VUmc, Amsterdam, The Netherlands
Citation Information: Hormone Molecular Biology and Clinical Investigation. Volume 6, Issue 1, Pages 193–199, ISSN (Online) 1868-1891, ISSN (Print) 1868-1883, DOI: 10.1515/HMBCI.2010.081, March 2011
- Published Online:
Background: Testosterone administration to hypogonadal men improves the metabolic syndrome. This study analyzed whether age, serum testosterone, body mass index/waist circumference, increment in testosterone values and C-reactive protein (CRP) predicted the outcome of testosterone administration.
Materials and methods: A total of 110 mainly elderly men, aged between 18 and 83 years (mean±SD=59.6±8.0) with baseline serum testosterone of 5.8–12.1 nmol/L (mean±SD=9.3±1.7) (n>14.0 nmol/L), received parenteral testosterone undecanoate whereupon serum testosterone normalized between 3 and 24 months.
Results: (i) The lower the baseline testosterone, the stronger the decreases in waist size and triglycerides. (ii) The greater the increment in serum testosterone, the stronger the decreases in low-density lipoprotein (LDL) cholesterol, triglycerides and glucose. (iii) Older age was associated with stronger beneficial effects on waist size, glucose and all lipids, but a small negative effect on high-density lipoprotein cholesterol. (iv) Obese men and men with the largest waist circumference showed the strongest declines over 2 years in weight, waist circumference and body mass index (BMI), and also in total cholesterol, triglycerides and glucose. Baseline BMI predicted a stronger decline in LDL cholesterol, but a smaller decline in CRP levels. (v) Higher baseline CRP predicted larger declines in levels of triglycerides, glucose and CRP. (vi) In the multivariate model, age, BMI and CRP were independent predictors of the strongest benefit of testosterone treatment on the metabolic syndrome.
Conclusions: Older men, particularly when obese with chronic low-grade inflammation benefited most of normalizing their testosterone levels, preferably if they reached mid-normal reference values.